| | 21 April 2022 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 14 April 2022, the Board, following a recommendation from the Remuneration Committee, granted new share options ("New Options") to the following Directors/PDMRs under the existing Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP'). The vesting of these options is based on achieving certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) growth against fixed targets and Total Shareholder Return (TSR) against a comparator group. The performance criteria have remained unchanged for the last eight years. Directors/PDMRs are required to hold the LTIPs for a period of two years following vesting.
| Director/PDMR | Options prior to grant | Options granted | Exercise price of New Options | Vesting Date of New Options | Resultant LTIP holdings |
| Chris Meredith Chief Executive Officer | 1,032,948
| 239,552
| Nil | 14/04/2025 | 1,272,500 |
| Eddie Johnson Chief Financial Officer | 258,426
| 89,832
| Nil | 14/04/2025 | 348,258 |
Advanced Medical Solutions Group plc also announces that on 14 April 2022, the Board, following a recommendation from the Remuneration Committee, granted new share options ("DAB Options") to the following Directors/PDMRs under the Advanced Medical Solutions Deferred Annual Bonus Plan (the '2014 DAB').
This award is in respect of the part of their bonus that the Directors/PDMRs are compulsorily required to defer for the 2021 financial year. These options vest at the end of three years. Details of the current DAB holdings of the Directors following these awards are shown below:
| Director/PDMR | Options prior to grant/exercise | Options granted | Exercise price of New Options | Vesting Date of New Options | Resultant holding |
| Chris Meredith Chief Executive Officer | 34,608 | 6,219 | 303.9 pence | 14/04/2025 | 40,827 |
| Eddie Johnson Chief Financial Officer | 10,854 | 1,883 | 303.9 pence | 14/04/2025 | 12,737 |
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||||
| a) | Name: Chris Meredith | ||||||||
2. | Reason for the notification | ||||||||
| a) | Position/status: Chief Executive Officer | ||||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||
| a) | Name: Advanced Medical Solutions Group plc | ||||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||||
| b) | Nature of the transactions: 1. Grant of 239,552 options under the Advanced Medical Solutions Long Term Incentive Plan on 14 April 2022 2. Grant of 6,219 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 14 April 2022 | ||||||||
| c) | Price(s) and volume(s):
1.
2.
| ||||||||
| d) | Aggregated information: Aggregated volume: n/a Aggregated price: n/a | ||||||||
| e) | Date of the transaction: 14/04/2022 | ||||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||||
| a) | Name: Eddie Johnson | ||||||||
2. | Reason for the notification | ||||||||
| a) | Position/status: Chief Financial Officer | ||||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||
| a) | Name: Advanced Medical Solutions Group plc | ||||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||||
| b) | Nature of the transactions: 3. Grant of options under the Advanced Medical Solutions Long Term Incentive Plan on 14 April 2022 4. Grant of options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 14 April 2022 | ||||||||
| c) | Price(s) and volume(s):
2.
2.
| ||||||||
| d) | Aggregated information: Aggregated volume: n/a Aggregated price: n/a | ||||||||
| e) | Date of the transaction: 14/04/2022 | ||||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End -
For further information, please visit www.admedsol.com or contact:
| Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
| Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer | |
| | |
| Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
| Mary-Jane Elliott / Matthew Neal / Matthew Cole | AMS@consilium-comms.com |
| | |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Daniel Adams / Gary Clarence | |
| | |
| HSBC Bank PLC (Broker) | Tel: 44 (0) 20 7991 8888 |
| Sam McLennan / Joe Weaving / Stephanie Cornish | |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
